MX2020010690A - Oxiesteroles y metodos de uso de los mismos. - Google Patents
Oxiesteroles y metodos de uso de los mismos.Info
- Publication number
- MX2020010690A MX2020010690A MX2020010690A MX2020010690A MX2020010690A MX 2020010690 A MX2020010690 A MX 2020010690A MX 2020010690 A MX2020010690 A MX 2020010690A MX 2020010690 A MX2020010690 A MX 2020010690A MX 2020010690 A MX2020010690 A MX 2020010690A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- oxysterols
- methods
- compounds
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporcionan compuestos de acuerdo a la Fórmula (I): (ver Fórmula) y sales farmacéuticamente aceptables de los mismos, y composiciones farmacéuticas de los mismos; en donde R1, R2, y R5 son como se definen en la presente. Los compuestos de la presente invención se consideran útiles para la prevención y tratamiento de una variedad de afecciones.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562189068P | 2015-07-06 | 2015-07-06 | |
US201662332931P | 2016-05-06 | 2016-05-06 | |
PCT/US2016/041175 WO2017007840A1 (en) | 2015-07-06 | 2016-07-06 | Oxysterols and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020010690A true MX2020010690A (es) | 2022-02-25 |
Family
ID=57686127
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021005052A MX2021005052A (es) | 2015-07-06 | 2016-07-06 | Oxiesteroles y métodos de uso de los mismos. |
MX2018000280A MX2018000280A (es) | 2015-07-06 | 2016-07-06 | Oxiesteroles y metodos de uso de los mismos. |
MX2020010690A MX2020010690A (es) | 2015-07-06 | 2016-07-06 | Oxiesteroles y metodos de uso de los mismos. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021005052A MX2021005052A (es) | 2015-07-06 | 2016-07-06 | Oxiesteroles y métodos de uso de los mismos. |
MX2018000280A MX2018000280A (es) | 2015-07-06 | 2016-07-06 | Oxiesteroles y metodos de uso de los mismos. |
Country Status (28)
Country | Link |
---|---|
US (3) | US11117924B2 (es) |
EP (2) | EP3319612B1 (es) |
JP (3) | JP2018519328A (es) |
KR (1) | KR20180026742A (es) |
CN (2) | CN113501855A (es) |
AU (3) | AU2016289971C1 (es) |
CA (1) | CA2991313C (es) |
CO (1) | CO2018000589A2 (es) |
CY (1) | CY1124620T1 (es) |
DK (1) | DK3319612T3 (es) |
ES (1) | ES2884086T3 (es) |
HR (1) | HRP20211282T1 (es) |
HU (1) | HUE055199T2 (es) |
IL (3) | IL282048B1 (es) |
LT (1) | LT3319612T (es) |
MA (1) | MA54851A (es) |
MD (1) | MD3319612T2 (es) |
MX (3) | MX2021005052A (es) |
MY (1) | MY197698A (es) |
PE (1) | PE20180482A1 (es) |
PH (1) | PH12018500061A1 (es) |
PL (1) | PL3319612T3 (es) |
PT (1) | PT3319612T (es) |
RS (1) | RS62220B1 (es) |
RU (2) | RU2742333C2 (es) |
SG (1) | SG10202002655VA (es) |
SI (1) | SI3319612T1 (es) |
WO (1) | WO2017007840A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2665571C2 (ru) | 2011-09-08 | 2018-08-31 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, композиции и их применения |
RS58166B1 (sr) | 2013-03-13 | 2019-03-29 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
RU2744267C2 (ru) | 2015-07-06 | 2021-03-04 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
CN113501855A (zh) | 2015-07-06 | 2021-10-15 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
AU2016289965B2 (en) * | 2015-07-06 | 2021-09-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
PT3436022T (pt) | 2016-04-01 | 2022-07-04 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
MA45598B1 (fr) | 2016-07-07 | 2021-09-30 | Sage Therapeutics Inc | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda |
AU2017337121B2 (en) | 2016-09-30 | 2022-01-27 | Sage Therapeutics, Inc. | C7 substituted oxysterols and methods as NMDA modulators |
IL266093B2 (en) | 2016-10-18 | 2024-02-01 | Sage Therapeutics Inc | Oxysterols and methods of using them |
EP4105223A1 (en) | 2016-10-18 | 2022-12-21 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
CN113121631B (zh) * | 2021-03-25 | 2023-02-03 | 西北农林科技大学 | 一种羊毛甾烷灵芝三萜类化合物、制备方法及应用 |
IL309208A (en) | 2021-06-11 | 2024-02-01 | Sage Therapeutics Inc | Neuroactive steroids for the treatment of Alzheimer's disease |
WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2259698A (en) | 1938-05-07 | 1941-10-21 | Rare Chemicals Inc | Physiologically effective substance and process of preparing same |
US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
US2673206A (en) | 1950-06-07 | 1954-03-23 | Schering Corp | 25-ethinyl steroids |
US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
JPS5324071B2 (es) | 1974-04-30 | 1978-07-18 | ||
US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
US4183852A (en) | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
US4174345A (en) | 1978-08-01 | 1979-11-13 | Kaiser Emil T | Synthesis of steroids |
US4269777A (en) | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
EP0205285B1 (en) | 1985-05-30 | 1989-08-09 | Taisho Pharmaceutical Co. Ltd | Vitamin d3 derivatives |
JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | 24,25−エポキシコレステロ−ル類の製造法 |
US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
DE69435286D1 (de) | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
DK1038880T3 (da) | 1994-02-14 | 2008-03-03 | Euro Celtique Sa | Androstaner og pregnaner til allosterisk modulering af GABA-receptor |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
EP0808325B1 (en) | 1994-11-23 | 2001-01-17 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
JPH08268917A (ja) | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
KR19990022323A (ko) | 1995-06-06 | 1999-03-25 | 씨. 랜 낸시 | 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드 |
US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
DE69630802T2 (de) | 1995-06-23 | 2004-08-12 | Novo Nordisk A/S | Meiose regulierende verbindungen. |
US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
EP0840612A1 (en) | 1995-07-24 | 1998-05-13 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
WO1997042215A1 (en) | 1996-05-06 | 1997-11-13 | Bionumerik Pharmaceuticals, Inc. | Process for preparing 27-hydroxy cholesterol and related derivatives |
JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | 24,25−ジヒドロキシコレステロールの製造法およびその合成中間体 |
AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
US7012069B2 (en) | 2001-05-03 | 2006-03-14 | Arch Development Corporation | Liver X receptor agonists |
CA2331299A1 (en) | 1998-05-11 | 1999-11-18 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
US8541600B2 (en) * | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
US6376530B1 (en) * | 1999-05-10 | 2002-04-23 | Merck & Co., Inc. | Cyclic amidines useful as NMDA NR2B antagonists |
GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
CN1111167C (zh) | 1999-10-22 | 2003-06-11 | 中国科学院上海有机化学研究所 | 3β-羟基-5-胆烯酸酯类衍生物、合成方法及其用途 |
CN1098273C (zh) | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25-和24s,25-二羟基甾体化合物 |
GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
JP2005508368A (ja) | 2001-11-08 | 2005-03-31 | ザ ユニバーシティー オブ シカゴ | 高コレステロール濃度に関連した疾患の治療方法 |
AU2002360489A1 (en) | 2001-12-07 | 2003-06-23 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
CN102727501A (zh) | 2002-03-27 | 2012-10-17 | 菲特法姆股份有限公司 | 皂角苷配基及其衍生物的用途 |
PE20040306A1 (es) | 2002-03-27 | 2004-05-29 | Phytopharm Plc | Metodos terapeuticos de sapogeninas y sus derivados |
GB0216621D0 (en) * | 2002-07-17 | 2002-08-28 | Imaging Res Solutions Ltd | Imaging compounds |
US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
EP1565453A4 (en) * | 2002-11-22 | 2007-10-10 | Merck & Co Inc | USE OF 2- (4-BENZYL) -1-PIPERIDINYL) METHYL | BENZIMIDAZOLE-5-OL DERIVATIVES AS ANTAGONISTS OF NR2B RECEPTORS |
WO2004055201A2 (en) | 2002-12-13 | 2004-07-01 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
US20070032464A1 (en) | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
WO2006050165A2 (en) | 2004-11-01 | 2006-05-11 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
EP1993558B1 (en) | 2006-02-27 | 2014-07-30 | The Regents of The University of California | Oxysterol compounds and the hedgehog pathway |
CN101164540A (zh) | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
WO2008057468A1 (en) | 2006-11-02 | 2008-05-15 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
CA2664126C (en) | 2006-11-21 | 2014-04-29 | Umecrine Ab | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders |
US8383823B2 (en) | 2007-06-20 | 2013-02-26 | Auspex Pharmaceuticals | Substituted N-aryl pyridinones |
GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
EP2207542A2 (en) | 2007-11-06 | 2010-07-21 | N.V. Organon | A method of hormone suppression in humans |
CA2707663C (en) | 2007-12-03 | 2017-05-30 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
AU2009206580A1 (en) | 2008-01-25 | 2009-07-30 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
KR101325374B1 (ko) * | 2008-02-19 | 2013-11-08 | 가부시키가이샤 오츠까 세이야꾸 고죠 | 신체 기능의 회복에 유용한 경구 또는 경장 조성물 |
US8497122B2 (en) * | 2008-04-11 | 2013-07-30 | Washington University | Biomarkers for Niemann-pick C disease and related disorders |
EP2296658A4 (en) | 2008-05-09 | 2014-01-15 | Univ Emory | ANTAGONISTS OF NMDA RECEPTORS USEFUL FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS |
US8207151B2 (en) * | 2008-05-28 | 2012-06-26 | Validus Biopharma Inc. | Non-hormonal steroid modulators of NF-κB for treatment of disease |
WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
US8822462B2 (en) | 2009-01-28 | 2014-09-02 | Emory University | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions |
JP2013500986A (ja) | 2009-07-29 | 2013-01-10 | ザ・ユニバーシティ・オブ・シカゴ | 肝臓x受容体アゴニスト |
WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
JP2011135864A (ja) * | 2009-12-30 | 2011-07-14 | Korea Univ Research & Business Foundation | Oct4及びBmi1、またはその上位調節子を用いて体細胞から胚幹細胞類似細胞への逆分化を誘導する組成物及びこれを用いた胚幹細胞類似細胞の製造方法 |
KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도 |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
GB201008047D0 (en) * | 2010-05-14 | 2010-06-30 | Ge Healthcare Ltd | Method of synthesis |
US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
WO2012142039A1 (en) | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
US20140335050A1 (en) | 2011-05-27 | 2014-11-13 | The General Hospital Corporation | Methods, compositions, and kits for the treatment of cancer |
WO2013019711A2 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
RU2665571C2 (ru) * | 2011-09-08 | 2018-08-31 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, композиции и их применения |
DK2763979T3 (en) | 2011-10-07 | 2019-04-01 | Takeda Pharmaceuticals Co | 1-arylcarbonyl-4-oxy-piperidine compounds for the treatment of neurodegenerative diseases |
EP2766380B1 (en) | 2011-10-14 | 2019-04-24 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
EP2841067A4 (en) | 2012-04-25 | 2016-04-13 | Univ California | MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME |
US9737522B2 (en) | 2012-08-09 | 2017-08-22 | Emory University | NMDA receptor modulators and uses related thereto |
WO2014028942A2 (en) | 2012-08-17 | 2014-02-20 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
CN107582544A (zh) * | 2012-08-24 | 2018-01-16 | 英特格拉斯疗法有限公司 | 用于增强治疗剂透皮递送的化学组合物和方法 |
SG10201706063UA (en) | 2012-12-18 | 2017-09-28 | Univ Washington | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same |
JP2016505038A (ja) | 2013-01-23 | 2016-02-18 | スファエラ ファーマ プライベート リミテッド | ミトコンドリア生合成ならびにミトコンドリア機能不全または欠乏に関連する疾患において使用するための11β−ヒドロキシステロイドの新規の化合物 |
CA2898863A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
RS58166B1 (sr) | 2013-03-13 | 2019-03-29 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
CA2905346A1 (en) | 2013-03-13 | 2014-10-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
CN105744937A (zh) | 2013-09-25 | 2016-07-06 | 范安德尔研究所 | 高效糖皮质激素 |
CN103655582B (zh) * | 2013-11-30 | 2015-05-27 | 浙江大学 | 一种环氧甾醇组合物及制备和用途 |
WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
US10016095B2 (en) * | 2014-10-03 | 2018-07-10 | Progressive International Corporation | Salad spinner |
EP3204011A4 (en) | 2014-10-07 | 2018-06-20 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
RU2744267C2 (ru) | 2015-07-06 | 2021-03-04 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
CN113501855A (zh) | 2015-07-06 | 2021-10-15 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
AU2016289965B2 (en) | 2015-07-06 | 2021-09-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
PT3436022T (pt) | 2016-04-01 | 2022-07-04 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
MA45598B1 (fr) | 2016-07-07 | 2021-09-30 | Sage Therapeutics Inc | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda |
CA3030420A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
AU2017337121B2 (en) | 2016-09-30 | 2022-01-27 | Sage Therapeutics, Inc. | C7 substituted oxysterols and methods as NMDA modulators |
EP4105223A1 (en) | 2016-10-18 | 2022-12-21 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
IL266093B2 (en) | 2016-10-18 | 2024-02-01 | Sage Therapeutics Inc | Oxysterols and methods of using them |
EP3595727A1 (en) | 2017-03-15 | 2020-01-22 | ModernaTX, Inc. | Lipid nanoparticle formulation |
BR112019027458A2 (pt) | 2017-06-23 | 2020-07-07 | Intercept Pharmaceuticals, Inc. | métodos e intermediários para a preparação de derivados de ácidos biliares |
JP7312169B2 (ja) | 2017-11-10 | 2023-07-20 | マリナス ファーマシューティカルズ インコーポレイテッド | 遺伝性てんかん性障害の処置に使用するガナキソロン |
-
2016
- 2016-07-06 CN CN202110635348.8A patent/CN113501855A/zh active Pending
- 2016-07-06 CA CA2991313A patent/CA2991313C/en active Active
- 2016-07-06 CN CN201680050744.1A patent/CN108135911B/zh active Active
- 2016-07-06 SI SI201631298T patent/SI3319612T1/sl unknown
- 2016-07-06 MX MX2021005052A patent/MX2021005052A/es unknown
- 2016-07-06 DK DK16821926.9T patent/DK3319612T3/da active
- 2016-07-06 ES ES16821926T patent/ES2884086T3/es active Active
- 2016-07-06 MX MX2018000280A patent/MX2018000280A/es unknown
- 2016-07-06 PE PE2018000037A patent/PE20180482A1/es unknown
- 2016-07-06 HU HUE16821926A patent/HUE055199T2/hu unknown
- 2016-07-06 WO PCT/US2016/041175 patent/WO2017007840A1/en active Application Filing
- 2016-07-06 AU AU2016289971A patent/AU2016289971C1/en active Active
- 2016-07-06 SG SG10202002655VA patent/SG10202002655VA/en unknown
- 2016-07-06 RS RS20211000A patent/RS62220B1/sr unknown
- 2016-07-06 PT PT168219269T patent/PT3319612T/pt unknown
- 2016-07-06 RU RU2018104245A patent/RU2742333C2/ru active
- 2016-07-06 IL IL282048A patent/IL282048B1/en unknown
- 2016-07-06 MY MYPI2018000010A patent/MY197698A/en unknown
- 2016-07-06 MD MDE20180513T patent/MD3319612T2/ro unknown
- 2016-07-06 KR KR1020187003209A patent/KR20180026742A/ko not_active Application Discontinuation
- 2016-07-06 RU RU2021100377A patent/RU2021100377A/ru unknown
- 2016-07-06 US US15/742,424 patent/US11117924B2/en active Active
- 2016-07-06 EP EP16821926.9A patent/EP3319612B1/en active Active
- 2016-07-06 EP EP20214736.9A patent/EP3812392A1/en active Pending
- 2016-07-06 JP JP2017568203A patent/JP2018519328A/ja not_active Withdrawn
- 2016-07-06 LT LTEP16821926.9T patent/LT3319612T/lt unknown
- 2016-07-06 MX MX2020010690A patent/MX2020010690A/es unknown
- 2016-07-06 PL PL16821926T patent/PL3319612T3/pl unknown
- 2016-07-06 MA MA054851A patent/MA54851A/fr unknown
-
2017
- 2017-12-24 IL IL256531A patent/IL256531B/en active IP Right Grant
-
2018
- 2018-01-05 PH PH12018500061A patent/PH12018500061A1/en unknown
- 2018-01-22 CO CONC2018/0000589A patent/CO2018000589A2/es unknown
-
2020
- 2020-12-24 JP JP2020215040A patent/JP2021046444A/ja not_active Withdrawn
-
2021
- 2021-08-06 US US17/396,034 patent/US11732000B2/en active Active
- 2021-08-10 HR HRP20211282TT patent/HRP20211282T1/hr unknown
- 2021-08-13 CY CY20211100733T patent/CY1124620T1/el unknown
- 2021-08-20 AU AU2021218230A patent/AU2021218230B2/en active Active
-
2022
- 2022-01-19 IL IL289976A patent/IL289976A/en unknown
- 2022-06-03 JP JP2022091046A patent/JP2022107795A/ja active Pending
-
2023
- 2023-06-29 US US18/216,057 patent/US20240132535A1/en active Pending
-
2024
- 2024-01-15 AU AU2024200254A patent/AU2024200254A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
MX2021005052A (es) | Oxiesteroles y métodos de uso de los mismos. | |
EP4316591A3 (en) | Oxysterols and methods of use thereof | |
MX2022005160A (es) | Oxisteroles y metodos de uso de los mismos. | |
PH12016502081A1 (en) | Compounds for treating spinal muscular atrophy | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
MX2018005890A (es) | Composiciones para tratar atrofia muscular espinal. | |
MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
SG10201804868PA (en) | Compounds for the inhibition of indoleamine-2,3-dioxygenase | |
EA201650031A1 (ru) | Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1 | |
PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
TN2017000031A1 (en) | Imidazopyridazine compounds | |
MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
TN2016000459A1 (en) | Cycloalkyl-linked diheterocycle derivatives. | |
WO2015002755A3 (en) | Compounds for the treatment of malaria | |
WO2015001541A3 (en) | Pharmaceutical film composition | |
MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. |